Clinical Trial Update: Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of pirtobrutinib, lisaftoclax, and rituximab in relapsed/refractory diffuse large B-cell lymphoma, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lisaftoclax (APG-2575)
• Pirtobrutinib (pirtobrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING